ITMCTR2100004767RecruitingPhase 4
To evaluate the clinical mechanism of Lianhua Qingwen Capsule on the systemic immune regulation of patients with new coronavirus pneumonia
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Ages
- 18 to 59 (—)
- Sex
- All
Inclusion Criteria
- •1. Aged 18 to 59 years;
- •2. Refer to the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Eighth Edition) formulated by the National Health Commission, with evidence of etiology or serology, and confirmed mild patients with new coronavirus pneumonia (mild clinical symptoms, no imaging Pneumonia manifestations).
- •3. The weight of male subjects must be >=50 kg, and the weight of female subjects >=45kg; body mass index (BMI=weight (kg)/height (m) square calculation) between 19 and 26 (including cutoff values));
- •4. The subject understands and accepts the process and restriction requirements of this study, voluntarily participates in this clinical study, and signs a written informed consent form.
Exclusion Criteria
- •1. Patients who have taken Xiyanping, Reduning, Tanreqing, Jinhua Qinggan, Banlangen and other antiviral Chinese medicines and/or immunomodulators, or drugs with immunomodulatory effects for external use within 1 week before being selected;
- •2. Currently suffering from diseases that seriously affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.
- •3. According to the judgment of the investigator, past or current diseases may affect the patients participation in the trial or the outcome of the study, including: malignant diseases, autoimmune diseases, liver and kidney diseases, hematological diseases, neurological diseases, and endocrine diseases Disease; or mental illness that may affect the compliance of the plan;
- •4. Patients who have a history of alcohol or banned drug abuse, or have taken or used alcohol products during the research period;
- •5. Serological examination (HBsAg, anti-HCV, anti-HIV or TPPA-Ab) with positive results;
- •6. Patients who have a history of drug dependence or drug abuse within 12 months, or those who tested positive for addictive substances during screening;
- •7. Patients with known allergies to Lianhua Qingwen ingredients or products, or allergies (including allergic reactions to other drugs);
- •8. Patients who have other factors that the researcher thinks are not suitable for participating in this research.
Investigators
Similar Trials
Recruiting
Phase 4
To evaluate the clinical mechanism of Lian-Hua Qing-Wen capsule on systemic immune regulation of influenza patientsinfluenzaITMCTR2100005453Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Recruiting
Phase 1
Evaluation of the clinical effect of Qinghua Xiaoyafang in improving the preoperative inflammatory state of patients with Crohn's disease and anal fistulaCrohn diseaseITMCTR2100004355Shuguang Hospital Affiliated to Shanghai University of traditional Chinese medicine
Recruiting
Not Applicable
Clinical study on Qinghua Liangxue Huayu Decoction combined with Shuigutie in the treatment of chronic liver failure complicated with ascites heat toxin and blood stasis syndromeChronic liver failureITMCTR2000003865Shanghai Municipal Hospital of TCM
Not yet recruiting
Phase 1
Clinical effect analysis and mechanism study on Qufu Shengjidan fo diabetic foot ulcerDiabetic foot ulcerITMCTR2000003244Chongqing Orthopaedic Hospital of Traditional Chinese Medicine
Recruiting
Phase 1
A randomized controlled clinical study of Qinghua Zhixie Recipe in Treating Irritable Bowel Syndrome with Spleen Deficiency and Damp-HeatIrritable Bowel SyndromeITMCTR2000003959Changshu Hospital of Traditional Chinese Medicine